Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The different gene expression between the overexpression of V2R and V279del in HEK293 cells with the treatment of AVP

ABSTRACT: To investigate the role of mutant V2R, V279del, on the downstream signaling, we ovexpressed V2R and V279del in HEK293 cell lines with AVP treatment

ORGANISM(S): Homo sapiens

PROVIDER: GSE207484 | GEO | 2025/07/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The different gene expression between the overexpression of V2R and V279del in HEK293 cells with the treatment of AVP

Project description:The different gene expression between the overexpression of V2R and V279del in HEK293 cells with the treatment of AVP

| PRJNA855902 | ENA

Vasopressin (AVP) and the V2R specific agonist dDAVP 7 day infusion into Aquaporin 1 knockout animals

Project description:Vasopressin, the antidiuretic hormone, acts on the renal collecting duct. In this experiment both vasopressin (AVP) and the V2R specific agonist dDAVP were infused into Aquaporin 1 knockout animals for 7 days. The aim of the experiment was to identify genes increased by vasopressin receptors in the renal medullary collecting ducts, in the absence of an increase in renal medullary osmolarity (the AQP1 knockouts are concentrating mechanism knockouts). All experiments used inner medulla tissue for the RNA isolation. Hybridizations were performed that compared kidney inner medulla total RNA from three control mice against kidney medulla total RNA from 3 mice infused with either arginine vasopressin (AVP) or des-amino-D-arginine vasopressin (dDAVP).

2007-10-06 | E-GEOD-5953 | biostudies-arrayexpress

Vasopressin (AVP) and the V2R specific agonist dDAVP 7 day infusion into Aquaporin 1 knockout animals

2007-10-07 | GSE5953 | GEO

Neutrophils stimulation with AVP promote IL36G release

Project description:We found that neutrophils were homing back to bone marrow and induced myelopoiesis after AVP treatment.This study investigated how neutrophils promoted HSC differentiation by comparing the expression of genes between control and AVP treatment neutrophils.We demonstrated that AVP treatment increased the expression of a variety of cytokine genes, especially IL36G, and the augmentation of bone marrow myelopoiesis involves IL36G-IL1RL2 axis.

2024-12-01 | GSE249379 | GEO

Vasopressin V2 Receptor, Tolvaptan, and ERK1/2 Phosphorylation in the Renal Collecting Duct

Project description:Activation of ERK1 and ERK2 is essential in regulation of a wide variety of cellular and physiological processes. In native inner medullary collecting ducts, vasopressin (AVP) working through the V2 subtype vasopressin receptor (V2R)-mediated activation of Gαs, inhibits ERK1 and ERK2 activity. However, it has been reported that V2R can signal independently of Gαs through the activation of β-arrestin, which activates ERK1 and ERK2. Vaptans, V2R antagonists that function as so-called “inverse agonists”, have the potential of promoting cell proliferation via β-arrestin-dependent ERK activation. Here we use the mpkCCD cell line which natively expresses V2R to investigate the effects of AVP, the V2-selective analog dDAVP, and tolvaptan on ERK1 and ERK2 phosphorylation and activation. We demonstrated that ERK1 and ERK2 phosphorylation in mpkCCD cells was significantly reduced by either AVP or dDAVP, in contrast to the increases seen in non-collecting duct cells overexpressing V2R. We also found that tolvaptan has a strong effect to increase ERK1 and ERK2 phosphorylation in the presence of dDAVP and that the tolvaptan effect to increase ERK1 and ERK2 phosphorylation is absent in PKA-null mpkCCD cells. Thus, it appears that the tolvaptan effect to increase ERK activation is PKA-dependent and, therefore, not mediated by the β-arrestin pathway. Overall, the studies show that AVP decreases and that tolvaptan increases ERK1 and ERK2 activation in cells expressing V2R at endogenous levels, and provide no evidence for a role for β-arrestin in the regulation of ERK1 and ERK2 activity.

2024-09-22 | GSE235936 | GEO

Vasopressin V2 Receptor, Tolvaptan, and ERK1/2 Phosphorylation in the Renal Collecting Duct II

2023-11-17 | GSE243773 | GEO

Homo sapiens

Project description:293T overexpressing V2R or V2R mutant, V279del, with the treatment of AVP

| PRJNA853075 | ENA

PKI overexpression in HEK293 cells

Project description:PKI overexpression in HEK293 cells

| PRJNA549932 | ENA

AVP promotes bone marrow myelopoiesis in depression

Project description:Sympathetic nerves have been implicated in the regulation of HSC homeostasis, we investigated whether sympathetic nerves regulated myeloid-biased differentiation of HSCs in CUMS mice. Transcriptome profiling (RNA-seq) and differential gene expression analysis of bone marrow cells were performed. In bone marrow cells of CUMS mice, the expression of arginine vasopressin receptor 2, a receptor of the stress-related neuroendocrine factor AVP, was upregulated through neuroactive ligand-receptor interaction pathway.

2024-12-01 | GSE249380 | GEO

AVP promotes bone marrow myelopoiesis in depression

Project description:AVP promotes bone marrow myelopoiesis in depression

| PRJNA1048923 | ENA